GSK137
GSK137 is an orally active, potent and selective B-cell lymphoma 6 (BCL6) inhibitor. GSK137 blocks the interaction between BCL6 and corepressors (e.g., SMRT), reducing the number of germinal center B cells. GSK137 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and B-cell-related tumors such as diffuse large B-cell lymphoma[1].
Product Specifications
CAS Number
2728727-91-9
UNSPSC
12352005
Hazard Statement
H302-H312-H332
Target
BCL6
Related Pathways
Immunology/Inflammation
Field of Research
Cancer; Inflammation/Immunology
Smiles
FC1=C(N2N=C1)N[C@@H](C[C@@H]2C3=C(N=CC=C3)C)C4=CC=CC5=C4C=CC(N)=N5
Molecular Formula
C21H19FN6
Molecular Weight
374.41
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501
References & Citations
[1]Pearce AC, et al. GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice. J Biol Chem. 2021 Aug;297 (2) :100928.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![CIB1 Mouse Monoclonal Antibody [Clone ID: OTI1D7]](https://cdn.genprice.uk/products/937/68dd18bb061270361e908a69/imageurl/cf811149.webp)
